Cresset Asset Management LLC Has $661,000 Stock Position in argenx SE (NASDAQ:ARGX)

Cresset Asset Management LLC trimmed its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 52.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,075 shares of the company's stock after selling 1,204 shares during the quarter. Cresset Asset Management LLC's holdings in argenx were worth $661,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. FMR LLC lifted its position in shares of argenx by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after buying an additional 824,750 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of argenx by 38,152.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock worth $89,391,000 after buying an additional 143,834 shares during the last quarter. Marshall Wace LLP lifted its position in shares of argenx by 184.7% during the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock worth $117,805,000 after buying an additional 124,271 shares during the last quarter. Capital World Investors lifted its position in shares of argenx by 5.1% during the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock worth $1,099,002,000 after buying an additional 86,687 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of argenx during the 4th quarter worth $43,543,000. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ARGX has been the subject of several recent analyst reports. William Blair restated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. JMP Securities set a $699.00 price objective on argenx in a research report on Wednesday. Guggenheim dropped their price objective on argenx from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Finally, Wells Fargo & Company upped their target price on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, twenty have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $698.11.

argenx Stock Performance

Shares of ARGX stock traded up $3.88 on Friday, hitting $565.63. The company had a trading volume of 433,461 shares, compared to its average volume of 324,080. The firm has a market cap of $34.54 billion, a P/E ratio of -642.76 and a beta of 0.57. The stock's 50-day moving average is $591.63 and its two-hundred day moving average is $612.92. argenx SE has a twelve month low of $356.38 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.26. The company had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Equities research analysts predict that argenx SE will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.